Table 1.
Baseline demographics and characteristics for patients with a baseline mMRC score of 0–1 and ≥2
| mMRC 0–1 (n=736) | mMRC ≥2 (n=883) | |
|---|---|---|
| Male, n (%) | 465 (63.2) | 521 (59.0) |
| Mean (SD) age, years | 64.6 (8.2) | 64.9 (8.5) |
| Race, n (%) | ||
| White | 711 (96.6) | 831 (94.1) |
| American Indian/Alaskan native | 1 (0.1) | 4 (0.5) |
| Asian | 3 (0.4) | 1 (0.1) |
| Black/African American | 21 (2.9) | 46 (5.2) |
| Native Hawaiian/Pacific Islander | 0 (0.0) | 1 (0.1) |
| Mean (SD) body mass index, kg/m2 | 27.2 (5.3) | 28.5 (6.2) |
| Smoking status, n (%) | ||
| Ex-smoker | 395 (53.7) | 462 (52.3) |
| Current smoker | 341 (46.3) | 421 (47.7) |
| mMRC, n (%) | ||
| 0 | 117 (15.9) | – |
| 1 | 619 (84.1) | – |
| 2 | – | 539 (61.0) |
| 3 | – | 298 (33.7) |
| 4 | – | 46 (5.2) |
| Mean (SD) BDI | 7.3 (1.9) | 5.8 (2.0) |
| Mean (SD) pre-bronchodilator screening | ||
| FEV1, L | 1.439 (0.499) | 1.268 (0.470) |
| Mean (SD) post-bronchodilator screening | ||
| FEV1, L | 1.633 (0.512) | 1.453 (0.482) |
| % of predicted normal FEV1 | 57.274 (12.452) | 53.252 (12.814) |
| FEV1 change from pre- to post-bronchodilator, L | 0.194 (0.149) | 0.185 (0.151) |
| FVC, L | 3.227 (0.884) | 2.967 (0.864) |
| FEV1/FVC, % | 51.083 (10.171) | 49.670 (10.596) |
| GOLD, n (%) | ||
| 1 (≥80%) | 1 (0.1) | 0 (0.0) |
| 2 (50-<80%) | 518 (70.4) | 522 (59.1) |
| 3 (30-<50%) | 216 (29.3) | 354 (40.1) |
| 4 (<30%) | 1 (0.1) | 7 (0.8) |
| Baseline pulmonary medication, n (%) | 562 (76.4) | 677 (76.7) |
| SAMA | 45 (6.1) | 79 (8.9) |
| LAMA | 262 (35.6) | 298 (33.7) |
| SABA | 370 (50.3) | 447 (50.6) |
| LABA | 266 (36.1) | 363 (41.1) |
| ICS | 256 (34.8) | 352 (39.9) |
| Xanthines | 5 (0.7) | 30 (3.4) |
| Mean (SE) SGRQ total score | 35.2 (0.6) | 48.9 (0.6) |
| GOLD, n (%) | ||
| A | 486 (66.0) | 0 (0.0) |
| B | 0 (0.0) | 483 (54.7) |
| C | 250 (34.0) | 0 (0.0) |
| D | 0 (0.0) | 400 (45.3) |
Abbreviations: BDI, baseline dyspnea index; FEV1, forced expiratory volume in 1 second; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; mMRC, modified Medical Research Council dyspnea scale; SABA, short-acting β2-agonist; SAMA, short-acting muscarinic antagonist; SE, standard error; SGRQ, St George’s Respiratory Questionnaire.